SJ-22-0015 – cBAF Inhibitors for Improving T Cell Immunotherapy

  • Researchersat St Jude identified proteins that help decide T cell fate and used that finding to improve CAR-T cell therapy in a solid tumor model.
  • The improvement comprises inhibition of Arid1a (a component of the BAF complex) to increase persistence of CAR-T cells in patients, leading toa more durable response.
  • This represents a generic improvement that can be used to increase the efficacy of any CAR-T cell therapy.

Abstract

Researchers at St Jude identified proteins that help decide T cell fate and used that finding to improve CAR-T cell therapy in a solid tumor model. The improvement comprises inhibition of Arid1a (a component of the BAF complex) to increase persistence of CAR-T cells in patients, leading to a more durable response. This represents a generic improvement that can be used to increase the efficacy of any CAR-T cell therapy. A Nature publication describing this finding that transient inhibition of Arid1a with RBD-K98645985 during CAR-T cell generation promote memory function and improve tumor control published June 22, 2022. Ao Guo, Hongling Huang, Zhexin Zhu, Mark J. Chen, Hao Shi, Sujing Yuan, Piyush Sharma, Jon P. Connelly, Swantje Liedmann, Yogesh Dhungana, Zhenrui Li, Dalia Haydar, Mao Yang, Helen Beere, Jason T. Yustein, Christopher DeRenzo, Shondra M. Pruett-Miller, Jeremy Chase Crawford, Giedre Krenciute, Charles W. M. Roberts, Hongbo Chi, Douglas R. Green. cBAF complex components and MYC cooperate early in CD8+ T cell fate. Nature, 2022; DOI: 10.1038/s41586-022-04849-0 We are seeking partners to develop and use this invention for gene and cell therapies. Contact: chad.riggs@stjude.org

Website

https://stjude.flintbox.com/technologies/E89BF405793549BC96F2A4BFF554169B

Advantages

Researchers at St Jude identified proteins that help decide T cell fate and used that finding to improve CAR-T cell therapy in a solid tumor model. The improvement comprises inhibition of Arid1a (a component of the BAF complex) to increase persistence of CAR-T cells in patients, leading to a more durable response.

Nature publication describing this finding that transient inhibition of Arid1a with RBD-K98645985 during CAR-T cell generation promote memory function and improve tumor control published June 22, 2022.

Potential Applications

This represents a generic improvement that can be used to increase the efficacy of any CAR-T cell therapy.

Contact Information

Name: Scott Elmer

Email: scott.elmer@stjude.org

Phone: 901-595-2756